Literature DB >> 27892951

Comparison of three or fewer high-dose chemotherapy cycles as salvage treatment in germ cell tumors in first relapse.

F Gössi1, M Spahn2, M Zweifel1, S Panagiotis3, A Mischo3, F Stenner4, U Hess5, D Berthold6, M Bargetzi7, J Schardt1, T Pabst1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27892951     DOI： 10.1038/bmt.2016.285

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

1.  High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables.

Authors:  J Beyer; A Kramar; R Mandanas; W Linkesch; A Greinix; J P Droz; J L Pico; A Diehl; C Bokemeyer; H J Schmoll; C R Nichols; L H Einhorn; W Siegert
Journal:  J Clin Oncol       Date:  1996-10       Impact factor: 44.544

2.  Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database.

Authors:  Anja Lorch; Caroline Bascoul-Mollevi; Andrew Kramar; Lawrence Einhorn; Andrea Necchi; Christophe Massard; Ugo De Giorgi; Aude Fléchon; Kim Margolin; Jean-Pierre Lotz; Jose Ramon Germà-Lluch; Thomas Powles; Christian Kollmannsberger; Jörg Beyer
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

3.  Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial.

Authors:  J-P Lotz; B Bui; F Gomez; C Théodore; A Caty; K Fizazi; G Gravis; R Delva; J Peny; P Viens; B Duclos; T De Revel; H Curé; J Gligorov; S Guillemaut; C Ségura; S Provent; J-P Droz; S Culine; P Biron
Journal:  Ann Oncol       Date:  2005-01-19       Impact factor: 32.976

4.  A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours.

Authors:  J-L Pico; G Rosti; A Kramar; H Wandt; V Koza; R Salvioni; C Theodore; G Lelli; W Siegert; A Horwich; M Marangolo; W Linkesch; G Pizzocaro; H-J Schmoll; J Bouzy; J-P Droz; P Biron
Journal:  Ann Oncol       Date:  2005-05-31       Impact factor: 32.976

5.  Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial.

Authors:  Anja Lorch; Antje Kleinhans; Andrew Kramar; Christian K Kollmannsberger; Jörg T Hartmann; Carsten Bokemeyer; Oliver Rick; Jörg Beyer
Journal:  J Clin Oncol       Date:  2012-01-30       Impact factor: 44.544

Review 6.  Salvage high-dose chemotherapy for germ cell tumors.

Authors:  Darren R Feldman; Thomas Powles
Journal:  Urol Oncol       Date:  2015-03-30       Impact factor: 3.498

7.  Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy.

Authors:  Anja Lorch; Jörg Beyer; Caroline Bascoul-Mollevi; Andrew Kramar; Lawrence H Einhorn; Andrea Necchi; Christophe Massard; Ugo De Giorgi; Aude Fléchon; Kim A Margolin; Jean-Pierre Lotz; Jose Ramon Germa Lluch; Thomas Powles; Christian K Kollmannsberger
Journal:  J Clin Oncol       Date:  2010-10-18       Impact factor: 44.544

8.  High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis.

Authors:  J Beyer; S Stenning; A Gerl; S Fossa; W Siegert
Journal:  Ann Oncol       Date:  2002-04       Impact factor: 32.976

9.  Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables.

Authors:  Daniel A Vaena; Rafat Abonour; Lawrence H Einhorn
Journal:  J Clin Oncol       Date:  2003-11-15       Impact factor: 44.544

10.  Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group.

Authors:  Anja Lorch; Christian Kollmannsberger; Joerg Thomas Hartmann; Bernd Metzner; Ingo G H Schmidt-Wolf; Wolfgang E Berdel; Florian Weissinger; Jan Schleicher; Gerlinde Egerer; Antje Haas; Rebekka Schirren; Jörg Beyer; Carsten Bokemeyer; Oliver Rick
Journal:  J Clin Oncol       Date:  2007-07-01       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.